Daily FNArena News

A glance through the latest expert views and predictions about commodities: upside for the iron ore price; near-term downside for global Metals & Mining sector; bullish view on medium-term copper price & scenarios for oil

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Independent Investment Research updates developments among Australia’s listed investment companies and provides comparative data

The New Criterion’s Tim Boreham navigates the choppy seas of a fraught Australian seafood-farming market

The ASX200 outperformed most overseas indices for the second consecutive month though lost -2.8% in September as 10-year bond yields climbed

Brokers generally approve of Brickworks’ FY23 results and envisage a positive outlook despite industry headwinds

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Zooming in on the latest news in global decarbonisation, in particular, the most recent IEA forecasts (one being for investment of US$4.5trn a year) and their implications; as well as the global march of ESG shortsellers; and more!

While interim results for Sigma Healthcare met expectations, brokers see margin upside from improved operating leverage